A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL‐2/BAX and p53 in colon cancer
British Journal of Pharmacology · 2024-01 · 181 (1) · 107-124
DOI: 10.1111/bph.16141 ↗At a glance
Journal article in British Journal of Pharmacology, 2024-01. Written by Jeyalakshmi Kandhavelu and 14 co-authors. Institution: Division of Oncology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Major MEDLINE topics: Colonic Neoplasms, Antineoplastic Agents, Colorectal Neoplasms. Cited 28 times so far (Crossref); 67 references. The full text is freely available (open access, CC BY 4.0). Funded by: Fundação para a Ciência e a Tecnologia, PT National Funds, South African Medical Research Council.
Abstract (original language)
Background and Purpose Colorectal cancer (CRC) is the second most lethal disease, with high mortality due to its heterogeneity and chemo‐resistance. Here, we have focused on the epidermal growth factor receptor (EGFR) as an effective therapeutic target in CRC and studied the effects of polyphenols known to modulate several key signalling mechanisms including EGFR signalling, associated with anti‐proliferative and anti‐metastatic properties. Experimental Approach Using ligand‐ and structure‐based cheminformatics, we developed three potent, selective alkylaminophenols, 2‐[(3,4‐dihydroquinolin‐1(2 H )‐yl)( p ‐tolyl)methyl]phenol (THTMP), 2‐[(1,2,3,4‐tetrahydroquinolin‐1‐yl)(4‐methoxyphenyl)methyl]phenol (THMPP) and N ‐[2‐hydroxy‐5‐nitrophenyl(4′‐methylphenyl)methyl]indoline (HNPMI). These alkylaminophenols were assessed for EGFR interaction, EGFR‐pathway modulation, cytotoxic and apoptosis induction, caspase activation and transcriptional and translational regulation. The lead compound HNPMI was evaluated in mice bearing xenografts of CRC cells. Key Results Of the three alkylaminophenols tested, HNPMI exhibited the lowest IC 50 in CRC cells and potential cytotoxic effects on other tumour cells. Modulation of EGFR pathway down‐regulated protein levels of osteopontin, survivin and cathepsin S, leading to apoptosis. Cell cycle analysis revealed that HNPMI induced G0/G1 phase arrest in CRC cells. HNPMI altered the mRNA for and protein levels of several apoptosis‐related proteins including caspase 3, BCL‐2 and p53. HNPMI down‐regulated the proteins crucial to oncogenesis in CRC cells. Assays in mice bearing CRC xenografts showed that HNPMI reduced the relative tumour volume. Conclusions and Implications HNPMI is a promising EGFR inhibitor for clinical translation. HNPMI regulated apoptosis and oncogenesis by modulating BCL‐2/BAX and p53 in CRC cell lines, showing potential as a therapeutic agent in the treatment of CRC.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Oncology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
- Molecular Signalling Lab, Faculty of Medicine and Health Technology, BioMediTech, Tampere University and Tays Cancer Centre, Tampere, Finland.
- BioMediTech Institute and Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
- Science Center, Tampere University Hospital, Tampere, Finland.
- Research and Publication Wing, Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India.
- Department of Physiology, Acibadem University School of Medicine, Atasehir, Istanbul, Turkey.
ORCID profiles: Saravanan Konda Mani, Meenakshisundaram Kandhavelu
Funding
- Fundação para a Ciência e a Tecnologia
- PT National Funds
- South African Medical Research Council
Cite
APA
Kandhavelu, J., Subramanian, K., Naidoo, V., Sebastianelli, G., Doan, P., Konda Mani, S., Yapislar, H., Haciosmanoglu, E., Arslan, L., Ozer, S., Thiyagarajan, R., Candeias, N. R., Penny, C., Kandhavelu, M., & Murugesan, A. (2024). A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL‐2/BAX and p53 in colon cancer. British Journal of Pharmacology. https://doi.org/10.1111/bph.16141
Vancouver
Kandhavelu J, Subramanian K, Naidoo V, Sebastianelli G, Doan P, Konda Mani S, et al. A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL‐2/BAX and p53 in colon cancer. British Journal of Pharmacology. 2024. doi:10.1111/bph.16141
BibTeX
@article{Kandhavelu2024,
author = {Kandhavelu, Jeyalakshmi and Subramanian, Kumar and Naidoo, Vivash and Sebastianelli, Giulia and Doan, Phuong and Konda Mani, Saravanan and Yapislar, Hande and Haciosmanoglu, Ebru and Arslan, Leman and Ozer, Samed and Thiyagarajan, Ramesh and Candeias, Nuno R and Penny, Clement and Kandhavelu, Meenakshisundaram and Murugesan, Akshaya},
title = {A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL‐2/BAX and p53 in colon cancer},
journal = {British Journal of Pharmacology},
year = {2024},
doi = {10.1111/bph.16141}
}
EUVIMED